Svetlana Nikic, Founder and Principal at Precision Oncology Consulting, shared on LinkedIn:
“Heading to ESMO26 today and still don’t have a clear picture on who is presenting what data?
Here’s a list of data presented using Illumina solutions.
We hope this kind of insights ahead of your busy time at the annual ESMO – European Society for Medical Oncology congress will be useful.
European Society for Medical Oncology (ESMO) Congress
October 23-27, 2026 | Madrid, Spain | Illumina
Friday, October 23 | Posters | 15:15-16:00
- Abstract Number: 1217P
Abstract Title: Novel candidate genes implicated in the pathogenesis and cisplatin resistance of testicular germ cell tumors
Presenting or Corresponding Author (Affiliation): Laura Matouskova (Prague, Czech Republic)
- Abstract Number: 2227P
Abstract Title: Incidence and patterns of co-occurrence of targetable genomic alterations in metastatic Prostate Cancer (mPC): Implications for personalized treatment stratification
Presenting or Corresponding Author (Affiliation): Daniela Arduini (Rome, Italy)
- Abstract Number: 3284P
Abstract Title: Real-world clinical actionability of comprehensive genomic profiling in advanced solid tumors: A prospective single-center pan-cancer cohort
Presenting or Corresponding Author (Affiliation): Hsieh-Ting Lin (Taipei City, Taiwan)
- Abstract Number: 3285P
Abstract Title: Characterization of G-protein-coupled estrogen receptor (GPER) and estrogen receptor in EGFR-mutated NSCLC leading to survival differences
Presenting or Corresponding Author (Affiliation): Robert Hsu (Los Angeles, United States of America)
- Abstract Number: 4259P
Abstract Title: Clinical utility of high-depth 74-gene liquid biopsy panel for the identification of actionable genomic alterations in advanced solid tumors: Single center experience
Presenting or Corresponding Author (Affiliation): Ashutosh Jain (Gurugram, India)
- Abstract Number: 4265P
Abstract Title: Genomic alterations (GA) and association with post-surgery circulating tumor DNA (cDNA) status in early-stage colon cancer (CC)
Presenting or Corresponding Author (Affiliation): Luca Lazzari (Milan, Italy)
- Abstract Number: 4390P
Abstract Title: Integrated proteomic profiling highlights peri-operative anabolic downregulation and tissue-repair upregulation in plasma of colorectal cancer (CRC) patients
Presenting or Corresponding Author (Affiliation): Giorgio Patelli (Milan, Italy)
- Abstract Number: 4423P
Abstract Title: Targeting endolysosomal trafficking in KRAS-mutant NSCLC: Multi-omic characterization and functional validation
Presenting or Corresponding Author (Affiliation): Victor Segui-Manzaneque (Valencia, Spain)
- Abstract Number: 4451P
Abstract Title: Mechanisms of insensitivity to the datopotamab deruxtecan (Dato-DXd) payload in subgroups of patients with advanced non-small cell lung cancer (NSCLC) in TROPION Lung01
Presenting or Corresponding Author (Affiliation): Nicolas Girard (Paris, France)
- Abstract Number: 4513P
Abstract Title: RNA as predictor for response and immune-related adverse event (irAEs) in metastatic urothelial carcinoma (mUC)
patients treated with pembrolizumab
Presenting or Corresponding Author (Affiliation): Ellen De Bruycker (Ghent, Belgium)
Saturday, October 24 | Poster | 12:00-12:45
- Abstract Number: 2080P
Abstract Title: Host inherited genetic variation and the risk of hepatitis following immune checkpoint immunotherapy (ICI) of melanoma
Presenting or Corresponding Author (Affiliation): Ahmad Tarhini (Tampa, United States of America)
Sunday, October 25 | Proffered Paper | 10:15-11:45
- Abstract Number: 6940
Abstract Title: Clinical benefit of matched targeted therapy in CNS tumors: Results from 349 patients in IMPRESS-Norway
Presenting or Corresponding Author (Affiliation): Pitt Niehusmann (Oslo, Norway)
Sunday, October 25 | Posters | 12:00-12:45
- Abstract Number: 190P
Abstract Title: A model-agnostic Al agent for automated molecular tumor board reports: A pan-cancer proof-of-concept
Presenting or Corresponding Author (Affiliation): Hsieh-Ting Lin (Taipei City, Taiwan)
- Abstract Number: 810P
Abstract Title: cDNA-guided adjuvant trials may miss the molecular residual disease (MRD) window: Evidence of early attrition during trial allocation
Presenting or Corresponding Author (Affiliation): Stefano Tamberi (Ravenna, Italy)
- Abstract Number: 2884P
Abstract Title: Distinct clinicopathological and molecular features of dual HER2/CLDN18.2-positive gastric cancer
Presenting or Corresponding Author (Affiliation): Takeru Wakatsuki (Koto-ku, Japan)
Monday, October 26 | Posters | 12:00-12:45
- Abstract Number: 1252P
Abstract Title: Niraparib first-line maintenance in optimally debulked ovarian cancer patients: Genomic alterations and survival by
molecular status
Presenting or Corresponding Author (Affiliation): Claudia Marchetti (Rome, Italy)
- Abstract Number: 1296P
Abstract Title: Genomic scar-defined homologous recombination deficiency (HRD) and tumor immune microenvironment in endometrial cancer (EC)
Presenting or Corresponding Author (Affiliation): Hiromichi Nakajima (Kashiwa, Japan)
- Abstract Number: 1489P
Abstract Title: Diagnostic and prognostic value of cerebrospinal fluid and plasma circulating tumor DNA in primary central nervous
system lymphoma
Presenting or Corresponding Author (Affiliation): Seoyoung Lim (Seoul, Republic of Korea)
- Abstract Number: 2686P
Abstract Title: RRAS2mt non-small cell lung cancer (NSCLC) defines a distinct subset of RASmt NSCLC
Presenting or Corresponding Author (Affiliation): Kristi Beshiri (Villejuif, France)
- Abstract Number: 4159P
Abstract Title: Germline genetic variants associated with VTE risk in patients with ALK, ROS-1 and other rare mutations in non-small cell lung cancer (NSCLC)
Presenting or Corresponding Author (Affiliation): Eduardo F. De Campos (Toronto, Canada)
Additional Abstracts | ePosters and Other
- Abstract Number: 1637eP
Abstract Title: Assessment of changes in oral microbiome in pre cancerous, oral cancer patients by 16S RNA metagenome sequencing seeking care at a government cancer hospital in North India
Presenting or Corresponding Author (Affiliation): Manisha Gupta (Lucknow, India)
- Abstract Number: 4580eP
Abstract Title: Paradoxical p53-associated miRNA signatures in uterine carcinosarcoma
Presenting or Corresponding Author (Affiliation): Susana N. Silva (Lisbon, Portugal)
- Abstract Number: 4529eP
Abstract Title: Gut microbiome composition at immunotherapy discontinuation predicts 3-year treatment-free survival: A prospective multicenter metagenomic analysis
Presenting or Corresponding Author (Affiliation): Chanul Y. Thennekoon (Minsk, Belarus)
- Abstract Number: 4817eP
Abstract Title: Next-Generation Sequencing in 100 urothelial carcinoma specimens with panel for 523 genes
Presenting or Corresponding Author (Affiliation): Maria I. Volkova (Moscow, Russian Federation).”
Read other articles about ESMO 2026 on OncoDaily.